Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a gynecologic oncology group study

Twenty-eight patients with advanced, measurable squamous carcinoma of the uterine cervix were treated with 62 courses of esorubicin at doses ranging from 20-35 mg/m2 every three weeks. All patients were evaluable for response and toxicity. All patients had received prior therapy including radiation...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 1989-07, Vol.7 (2-3), p.235-238
Main Authors: MCGUIRE, W. P, BLESSING, J. A, YORDAN, E, BEECHAM, J
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic agents
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Carcinoma, Squamous Cell - drug therapy
Chemotherapy
Doxorubicin - adverse effects
Doxorubicin - analogs & derivatives
Doxorubicin - therapeutic use
Drug Evaluation
Female
Hematologic Diseases - chemically induced
Humans
Medical sciences
Middle Aged
Neoplasm Metastasis
Pharmacology. Drug treatments
Uterine Cervical Neoplasms - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Twenty-eight patients with advanced, measurable squamous carcinoma of the uterine cervix were treated with 62 courses of esorubicin at doses ranging from 20-35 mg/m2 every three weeks. All patients were evaluable for response and toxicity. All patients had received prior therapy including radiation therapy in 28, chemotherapy in 23, and surgery in 11. All patients were Gynecologic Oncology Group (GOG) performance status 0, 1 or 2. There were no responses seen. Severe (grade 3 or 4) leukopenia, thrombocytopenia, and anemia were seen in 13, 3, and 9 patients, respectively. Gastrointestinal toxicity as well as alopecia were the other adverse effects. Mucositis and phlebitis were not seen. Neither clinical congestive cardiomyopathy nor decrement in left ventricular ejection fraction was observed. Lack of response in association with moderate toxicity using this dose and schedule of esorubicin in squamous carcinoma of the cervix previously treated with chemotherapy makes further study as a salvage agent unwarranted.
ISSN:0167-6997
1573-0646
DOI:10.1007/BF00170865